| abstract |
FIELD: pharmaceuticals.SUBSTANCE: present invention refers to compounds of formula (1a) or its pharmaceutically acceptable salt, where q equals 1; r is equal to 1 or 2; s equals 0 or 1, wherein sum of r and s equals 1 or 2; Q is CR1R2NR5R6, NR5R6, OR7, SR7; R1is selected from hydrogen or C1-6alkyl group; R2is selected from hydrogen or C1-6alkyl group; R3denotes hydrogen; R4represents hydrogen or C1-6alkyl group; R5is selected from OR7; C1-6non-aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms and in which one or two but not all carbon atoms of the hydrocarbon group can be optionally replaced with a heteroatom selected from O, N and S and their oxidised forms; and a group W or CH2W, where W is 5- or 6-member aromatic ring containing 0, 1, 2 or 3 heteroatoms selected from O and N; R6is selected from COR7; COOR7; CH2COR7; CH2COOR7; C1-6non-aromatic hydrocarbon group, which is optionally substituted with one to six fluorine atoms and in which one or two but not all carbon atoms of the hydrocarbon group can optionally be replaced with heteroatom O; or C3-6cycloalkyl group; and R7is selected from hydrogen, C1-6alkyl group, which is optionally substituted with one to six fluorine atoms and in which one carbon atom can optionally be replaced with heteroatom N; and when Q is group OR7or SR7, R7is selected from a group W or (C1-4alkyl)W, where W is phenyl; and the dashed line, which shows an optional second carbon-carbon bond, is absent. In addition, specific compounds, pharmaceutical compositions containing compounds of formula (1a) or specific compounds are disclosed.(1a).EFFECT: there are prepared and described new compounds which are muscarinic receptor and/or M4agonists and are suitable for treating diseases mediated by muscarinic receptors M1/M4.22 cl, 1 dwg, 4 tbl |